Currently, Relmada Therapeutics Inc [RLMD] is trading at $0.75, up 3.92%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RLMD shares have gain 21.95% over the last week, with a monthly amount glided 132.63%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Relmada Therapeutics Inc [NASDAQ: RLMD] stock has seen the most recent analyst activity on December 05, 2024, when Mizuho downgraded its rating to a Neutral and also revised its price target to $1 from $23. Previously, Jefferies upgraded its rating to Buy on September 17, 2024, and elevated its price target to $13. On June 05, 2024, downgrade downgraded it’s rating to Sell and revised its price target to $2 on the stock. Truist downgraded its rating to a Hold and decreased its price target to $10 on October 14, 2022. Guggenheim downgraded its rating to a Neutral. Goldman downgraded its rating to Neutral for this stock on October 14, 2022, and downed its price target to $8. In a note dated October 13, 2022, Oppenheimer downgraded an Perform rating on this stock and revised its target price from $64 to $7.
This stock has fluctuated between a low of $0.24 and a high of $4.47 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $5.67 within the next 12 months. Relmada Therapeutics Inc [NASDAQ: RLMD] shares were valued at $0.75 at the most recent close of the market. An investor can expect a potential return of 656.0% based on the average RLMD price forecast.
Analyzing the RLMD fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -2.74, Equity is -1.81 and Total Capital is -3.52.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7050 points at the first support level, and at 0.6601 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7819, and for the 2nd resistance point, it is at 0.8139.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Relmada Therapeutics Inc [NASDAQ:RLMD] is 5.29. As well, the Quick Ratio is 5.29, while the Cash Ratio is 0.22.
Transactions by insiders
Recent insider trading involved Kelly Paul Edward, Chief Operating Officer, that happened on May 16 ’25 when 0.2 million shares were purchased. Chief Financial Officer, Shenouda Maged completed a deal on May 19 ’25 to buy 90000.0 shares. Meanwhile, Chief Financial Officer Shenouda Maged bought 60000.0 shares on May 20 ’25.
